MedPath

Drug Farm Partners with NIH to Develop Treatment for ROSAH Syndrome

7 months ago1 min read
Drug Farm, a clinical-stage biopharmaceutical company, has announced a partnership with the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to develop DF-003, an oral drug targeting the disease-causing mutant alpha kinase-1 (ALPK1), which is responsible for ROSAH syndrome. This agreement focuses on advancing DF-003, a first-in-class ALPK1 inhibitor, through clinical trials to assess its safety, pharmacokinetics, and efficacy in treating ROSAH syndrome.
ROSAH syndrome is a rare, autosomal dominant autoinflammatory genetic disease characterized by symptoms including retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache. The disease is caused by mutations in the ALPK1 gene, leading to a range of symptoms such as progressive visual decline, optic disc elevation, uveitis, and retinal nerve degeneration. Patients often experience inflammatory features like low-grade fevers, arthralgia, headaches, and elevated levels of inflammatory cytokines.
DF-003 has shown preclinical efficacy in a transgenic ROSAH mouse model and has completed Phase 1 evaluation in healthy subjects. The upcoming clinical trial, sponsored by Drug Farm in collaboration with NIAID, aims to further evaluate DF-003's potential as a therapeutic option for ROSAH syndrome patients. This partnership represents a crucial advancement in the search for effective treatments for this debilitating condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.